Broadcasting News

Kwon Yuri Leaves SM After 19 Years, Says "Girls' Generation Activities Will Continue"

Contract expires on August 31 "I’ll be cheering you on as you embark on this new journey."

Gim Ga Yeong
2026-07-31 14:39:38
[Edaily Starin Gim Ga Yeong Reporter] Actress Kwon Yuri, formerly of Girls’ Generation, has seen her exclusive contract with SM Entertainment expire.
Kwon Yuri
SM Entertainment announced in an official press release on the 31st, “We sincerely thank all the fans who have shown unwavering love for Kwon Yuri,” adding, “After in-depth discussions with Kwon Yuri, we have mutually agreed to conclude our 19-year partnership effective August 31.”
Kwon Yuri debuted in 2007 as a member of the girl group Girls’ Generation and gained immense popularity both domestically and internationally. She later ventured into acting, appearing in productions such as *The Accused*, *Bossam: Stealing Fate*, *Good Job*, and *The Art of Negotiation*, and has been recognized as an actress.
SM Entertainment stated, “It has been a precious time for SM Entertainment to have been part of Kwon Yuri’s entire journey—from her debut with Girls’ Generation in 2007, where she led the global K-pop craze and helped the group grow into an iconic act of its era, to her shining success as an actress,” and "We express our deep gratitude to Kwon Yuri, who has shone brilliantly as an ‘all-rounder artist,’ excelling across various fields including music, acting, variety shows, and hosting."
They continued, “Although her exclusive contract with our company has ended, she will continue her activities as a member of Girls’ Generation as before,” and added, “We will cheer on Kwon Yuri as she embarks on her new journey.”

Economy

Corporation

IT·Science

Economy

[VC's Pick] Big Money Flows into Smart 'Medical AI and Robotics' Technologies That Replace Human Hands

This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
2026-11-21 10:04:03

Corporation

Celltrion Sees Full-Scale Results from Direct Sales in the U.S. … “Projected Operating Profit of 2.4 Trillion Won Next Year”

Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
2026-11-21 06:01:02

IT·Science

Penetrium Bioscience and AprilBio Rally as AriBio-Linked Stocks Diverge [K-Bio Pulse]

South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…
2026-11-21 08:17:02